{"id":"W4318485463","doi":"10.1038/s41375-023-01829-9","title":"Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL","year":2023,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":135,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; National Institute for Health and Care Research; Novartis Pharmaceuticals Corporation","keywords":"Bosutinib; Discontinuation; Medicine; Tolerability; Internal medicine; Adverse effect; Imatinib; Myeloid leukemia; Clinical endpoint; Oncology; Nilotinib; Gastroenterology; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003753857,0.0007915334,0.002903434,0.0003863679,0.0005129209,0.001370174,0.0005899149,0.001337745,0.005887702],"category_scores_gemma":[0.003078444,0.0003554679,0.00439189,0.0006342672,0.0004120266,0.001749934,0.0005587653,0.004225099,0.0008499625],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009356617,"about_ca_system_score_gemma":0.0006587559,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009368227,"about_ca_topic_score_gemma":0.001780751,"domain_scores_codex":[0.998884,0.000346217,0.0001116673,0.0001942674,0.0001482949,0.0003155876],"domain_scores_gemma":[0.9969176,0.0007958218,0.0009743394,0.0002920629,0.0002286914,0.0007914682],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8707796,0.006923163,0.01503542,0.0009061545,0.006226169,0.000161437,0.0001327737,0.001431466,0.005013882,0.0001746085,0.00224392,0.09097142],"study_design_scores_gemma":[0.2096193,0.4771824,0.2725051,0.0006497509,0.01663776,0.0006871176,0.0002754164,0.004032866,0.006393326,0.000977871,0.01087038,0.0001688568],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9765881,0.01686506,0.0003721503,0.0006104152,0.0003316056,0.0003062615,0.00218871,0.00005945054,0.002678163],"genre_scores_gemma":[0.9922125,0.00230405,0.0001707152,0.0007058874,0.0002888853,0.0002906329,0.002232447,0.00001092345,0.00178399],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005887702,"threshold_uncertainty_score":0.01985252,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02015551723185398,"score_gpt":0.2940192947944369,"score_spread":0.2738637775625829,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}